Cephalon, Inc.

57 patents currently held · Updated Nov 15, 2026

19 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 4 name spellings.

Ending by 2030

Apr 2027

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Nov 19, 2026
The maintenance fee for Treatment of chronic inflammation with a 1,2,4-triazolo [1,5a] pyridine derivative (US 9,034,876) comes due Nov 19, 2026. Unpaid by May 19, 2027, it lapses early.
1 fee due Jan 18, 2027
The maintenance fee for 1,4-Substituted Piperidine Derivatives (US 11,702,388) comes due Jan 18, 2027. Unpaid by Jul 19, 2027, it lapses early.
1 fee due Mar 15, 2027
The maintenance fee for Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor (US 9,132,128) comes due Mar 15, 2027. Unpaid by Sep 15, 2027, it lapses early.
1 fee due Jun 30, 2027
The maintenance fee for Solid forms of bendamustine hydrochloride (US 10,517,852) comes due Jun 30, 2027. Unpaid by Jan 3, 2028, it lapses early.
2 fees due Jul 23, 2027
1 fee due Sep 3, 2027
The maintenance fee for Use of Reslizumab to Treat Moderate to Severe Eosinophilic Asthma (US 10,577,414) comes due Sep 3, 2027. Unpaid by Mar 3, 2028, it lapses early.
1 fee due Oct 28, 2027
The maintenance fee for Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor (US 10,632,119) comes due Oct 28, 2027. Unpaid by Apr 28, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

1 term has ended since Aug 17, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US 7,919,502	Pyridopyrazines and derivatives thereof as ALK and c-MET inhibitors In force Term ends Apr 30, 2027 · From the USPTO record	In force	Term ends Apr 30, 2027	From the USPTO record
US 8,080,561	Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors In force Term ends Apr 30, 2027 · From the USPTO record	In force	Term ends Apr 30, 2027	From the USPTO record
US 7,601,716	Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors In force Term ends May 30, 2027 · From the USPTO record	In force	Term ends May 30, 2027	From the USPTO record
US 7,858,121	Effervescent oral fentanyl dosage form and methods of administering fentanyl In force Term ends Jun 15, 2028 · From the USPTO record	In force	Term ends Jun 15, 2028	From the USPTO record
US 7,862,832	Generally linear effervescent oral fentanyl dosage form and methods of administering In force Term ends Mar 4, 2029 · From the USPTO record	In force	Term ends Mar 4, 2029	From the USPTO record
US 7,862,833	Effervescent oral opiate dosage forms and methods of administering opiates In force Term ends Mar 6, 2029 · From the USPTO record	In force	Term ends Mar 6, 2029	From the USPTO record
US 8,445,524	Solid forms of bendamustine hydrochloride In force Term ends Mar 26, 2029 · From the USPTO record	In force	Term ends Mar 26, 2029	From the USPTO record
US 8,669,279	Solid forms of bendamustine hydrochloride In force Term ends Mar 26, 2029 · From the USPTO record	In force	Term ends Mar 26, 2029	From the USPTO record
US 8,883,836	Solid forms of bendamustine hydrochloride In force Ends no later than Mar 26, 2029 · From the USPTO record	In force	Ends no later than Mar 26, 2029	From the USPTO record
US 9,533,955	Solid forms of bendamustine hydrochloride In force Ends no later than Mar 26, 2029 · From the USPTO record	In force	Ends no later than Mar 26, 2029	From the USPTO record

10 of 57 patents shown.

Pro members see all 57.

Pro members: see all 57 patents

Also on record, not counted in the 57: 19 patents in force now held by others · 117 lapsed for an unpaid fee · 137 ended at full term · 1 surrendered on reissue · 1 with no computed term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

8 pending · 9 abandoned · 69 no status recorded

List them